Cargando…

The Society for Immunotherapy of Cancer clinical practice guideline on immunotherapy for hepatocellular carcinoma

Detalles Bibliográficos
Autor principal:	Kudo, Masatoshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2023
Materias:	Editorial Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10129894/ https://www.ncbi.nlm.nih.gov/pubmed/37124680 http://dx.doi.org/10.21037/hbsn-23-122

Ejemplares similares

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma
por: Greten, Tim F, et al.
Publicado: (2021)

Immunotherapy for the treatment of hepatocellular carcinoma: finally in clinical practice
por: Celsa, Ciro, et al.
Publicado: (2023)

Advances in Immunotherapy for Hepatocellular Carcinoma
por: Hagiwara, Satoru, et al.
Publicado: (2023)

Drug-Off Criteria in Patients with Hepatocellular Carcinoma Who Achieved Clinical Complete Response after Combination Immunotherapy Combined with Locoregional Therapy
por: Kudo, Masatoshi
Publicado: (2023)

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma
por: Neelapu, Sattva S, et al.
Publicado: (2020)

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gastrointestinal cancer
por: Kelly, Ronan J, et al.
Publicado: (2023)

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer
por: Disis, Mary L, et al.
Publicado: (2023)

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer
por: Emens, Leisha A, et al.
Publicado: (2021)

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer
por: Galsky, Matthew D, et al.
Publicado: (2021)

The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia
por: Boyiadzis, Michael M, et al.
Publicado: (2020)

Correction: Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma
Publicado: (2021)

Correction: Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer
Publicado: (2023)

Correction: Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer
Publicado: (2021)

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
por: Govindan, Ramaswamy, et al.
Publicado: (2022)

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancer
por: Silk, Ann W, et al.
Publicado: (2022)

Lipids link immune suppression to effective immunotherapy in steatotic hepatocellular carcinoma
por: Li, Bing, et al.
Publicado: (2023)

Adjuvant atezolizumab-bevacizumab after curative therapy for hepatocellular carcinoma
por: Kudo, Masatoshi
Publicado: (2023)

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0
por: Pavlick, Anna C, et al.
Publicado: (2023)

Introducing the society for immunotherapy of cancer’s new journal: journal for immunoTherapy of cancer
por: Romero, Pedro J, et al.
Publicado: (2013)

Challenges and Future Trends of Hepatocellular Carcinoma Immunotherapy
por: Rizzo, Alessandro, et al.
Publicado: (2022)

Society for immunotherapy of cancer (SITC) statement on the proposed changes to the common rule
por: Kaufman, Howard L., et al.
Publicado: (2016)

Obesity and non-alcoholic steatohepatitis in immunotherapy for hepatocellular carcinoma
por: Shiina, Shuichiro, et al.
Publicado: (2023)

Scientific Rationale for Combined Immunotherapy with PD-1/PD-L1 Antibodies and VEGF Inhibitors in Advanced Hepatocellular Carcinoma
por: Kudo, Masatoshi
Publicado: (2020)

The tango of immunotherapy and targeted therapy in metastatic renal cell carcinoma
por: Rathi, Nityam, et al.
Publicado: (2019)

Immunotherapy in cervical cancer: the advent of precision medicine
por: De Felice, Francesca, et al.
Publicado: (2020)

Combining immunotherapy and radiotherapy in hepatocellular carcinoma: the importance of irradiated tumor burden and the possible role of a low dose radiotherapy induction strategy
por: Grassberger, Clemens, et al.
Publicado: (2023)

Consensus Guidelines on Practical Issues of Immunotherapy-Canadian Society of Allergy and Clinical Immunology (CSACI)
por: Leith, Eric, et al.
Publicado: (2006)

Durvalumab plus tremelimumab in unresectable hepatocellular carcinoma
por: Kudo, Masatoshi
Publicado: (2022)

Cancer immunotherapy by immunosuppression
por: Prehn, Richmond T, et al.
Publicado: (2010)

Immunotherapy for penile cancer
por: Buonerba, Carlo, et al.
Publicado: (2017)

Oncolytic immunotherapy for metastatic cancer: lessons and future strategies
por: Guo, Zong-Sheng
Publicado: (2020)

Tarlatamab: the promising immunotherapy on its way from the lab to the clinic
por: Tang, Daolin, et al.
Publicado: (2023)

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events
por: Maus, Marcela V, et al.
Publicado: (2020)

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events
por: Brahmer, Julie R, et al.
Publicado: (2021)

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma
por: McNeel, Douglas G., et al.
Publicado: (2016)

Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma
por: Kamat, Ashish M., et al.
Publicado: (2017)

Immunotherapy in Hepatocellular Carcinoma
por: Fulgenzi, Claudia A. M., et al.
Publicado: (2021)

Immunotherapies for hepatocellular carcinoma
por: Liu, Justin K. H., et al.
Publicado: (2021)

T and NK Cell-Based Immunotherapy in Chronic Viral Hepatitis and Hepatocellular Carcinoma
por: Fisicaro, Paola, et al.
Publicado: (2022)

Role of β-Catenin Activation in the Tumor Immune Microenvironment and Immunotherapy of Hepatocellular Carcinoma
por: Morita, Masahiro, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_fves1hjgs8qkvmhmhkgunlclnk